Pulse Biosciences, Inc. PLSE
58.17 USD +4.88 (+9.16%)
At closeNov 9, 2026, 5:14 PM EST
58.24 +0.07 +0.12%
After hours · Nov 9, 5:14 PM ET
53.36 Day range 58.94
12.56 52-week range 58.94
- YTD
- +323.67%
- 1 year
- +276.26%
News
benzinga.com Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $74 Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $58 to $74.
benzinga.com Needham Maintains Buy on Pulse Biosciences, Raises Price Target to $64 Needham analyst Mike Matson maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $58 to $64.
benzinga.com Pulse Biosciences Presents Six-Month Interim Results From PRECISE-BTN Thyroid Nodule Study, At 95th ATA Annual Meeting 86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatment, with significant improvements in symptoms and quality of life and no…
seekingalpha.com Pulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call Transcript Pulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call Transcript
benzinga.com Pulse Biosciences Q3 2026 Earnings Call Transcript Pulse Biosciences (NASDAQ:PLSE) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical dataPulse Biosciences, Inc. (NASDAQ:PLSE), the…
benzinga.com Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60 Oppenheimer analyst Suraj Kalia maintains Pulse Biosciences (NASDAQ:PLSE) with a Outperform and raises the price target from $35 to $60.
benzinga.com Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58 Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $43 to $58.
benzinga.com TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
benzinga.com This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated bullish coverage on HCA, GRDN, TTC, MRVL and PLSE, setting price targets of $495, $52, $120, $270 and $70.- benzinga.com BTIG Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $70 BTIG analyst Marie Thibault initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $70.
benzinga.com Pulse Biosciences Files Prospectus Supplement For Up To $85M At-The-market Common Stock Offering Via Mizuho; Terminates TD Cowen Distribution Agreement On Sept 14, 2026 With $1M Unsold On September 15, 2026, Pulse Biosciences, Inc. (the "Company") entered into an equity distribution agreement (the "Sales Agreement") with Mizuho Securities USA LLC ("Mizuho") as sales agent,- benzinga.com Pulse Biosciences Concludes 100 Patient Enrollment in PRECISE-BTN Study of nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones…
benzinga.com Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…- benzinga.com Freedom Capital Markets Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $73 Freedom Capital Markets analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $73.
benzinga.com Top 3 Health Care Stocks That May Keep You Up At Night In Q3 As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to momentum investors, according to the RSI indicator.
benzinga.com This Okta Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday Top Wall Street analysts changed their outlook on top stocks. See analyst ratings and price targets for PMT, ALAB.
benzinga.com This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday WALL analysts changed outlook on top names. See upgrades, downgrades & initiations on analyst ratings page. Workday downgraded, price target cut.
benzinga.com This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. See analyst rating changes on Benzinga's page. Analysts have positive views on ONTO stock.- benzinga.com Needham Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $58 Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $58.
- benzinga.com Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $43 Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $32 to $43.
- benzinga.com Pulse Biosciences Q2 EPS $(0.36), Inline, Sales $434.000K Miss $533.333K Estimate Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 28.57 percent decrease over losses of $(0.28) per share from the…
benzinga.com Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc…
benzinga.com Canaccord Genuity Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $32 Canaccord Genuity analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $32.- benzinga.com Pulse Biosciences Co‑Chairmen, CEO Purchase ~$13.3M In Shares Via ATM Program Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan…
benzinga.com Earnings Scheduled For May 4, 2026 - benzinga.com Pulse Biosciences Q1 EPS $(0.27) Beats $(0.32) Estimate, Sales $401.000K Beat $400.000K Estimate Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.32) by 12.9 percent. This is a 8 percent decrease over losses of…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Pulse Biosciences Enrolls First Patient In Its NANOPULSE-AF Study Of nPulse Cardiac Catheter System For Recurrent, Drug-Resistant, Symptomatic Paroxysmal Atrial Fibrillation The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research…- benzinga.com Pulse Biosciences' Long-Term AFib Clinical Data Demonstrates that Nanosecond Pulsed Field Ablation Delivers Speed, Safety, And Long-Term Durable Efficacy For Atrial Fibrillation (AFib). Pulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and
- benzinga.com Pulse Biosciences Begins First Human Study Of New Device To Treat Small Thyroid Cancer Tumors Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first
benzinga.com Pulse Biosciences Q4 Earnings Report: What Investors Need to Know - benzinga.com Pulse Biosciences Q4 EPS $(0.26) Beats $(0.31) Estimate, Sales $264.000K Beat $250.000K Estimate Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 16.13 percent increase over losses of…
- benzinga.com Earnings Scheduled For February 19, 2026
benzinga.com A Glimpse of Pulse Biosciences's Earnings Potential 
benzinga.com What's Going With Pulse Biosciences Stock On Monday? Pulse Biosciences stock rises after new study data showed strong early results for its heart treatment device, helping shares outperform a weak broader market.
benzinga.com Pulse Biosciences Heart Device Data Fuels Stock Surge Pulse Biosciences stock trading higher on promising clinical data for atrial fibrillation treatment, with potential for further growth.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Strategy Posts Upbeat Q4 Results, Joins SunOpta, BILL Holdings, Mitek Systems And Other Big Stocks Moving Higher On Friday U.S. stocks were higher, with the Dow Jones index gaining more than 700 points on Friday.- benzinga.com Pulse Biosciences Teams Up With MD Anderson To Test New Thyroid Cancer Treatment In FDA-Approved Study Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA…
- benzinga.com Pulse Biosciences Q3 EPS $(0.29) Beats $(0.31) Estimate, Sales $86.000K Miss $500.000K Estimate Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.31) by 6.45 percent. This is a 38.1 percent decrease over losses of…
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com Pulse Biosciences Announces Enrollment Of First Patient In NANOCLAMP AF Study For Treatment Of Atrial Fibrillation First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical ProcedurePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™…
- benzinga.com Pulse Biosciences Announces Late-Breaking Clinical Study Results From nPulse Cardiac Surgical System First-In-Human Feasibility Study At 39th European Association For Cardio-Thoracic Surgery Annual Meeting Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical SystemPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology…
benzinga.com Pulse Biosciences Begins First Study Using Nanosecond PFA Tech To Treat Benign Thyroid Nodules Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful…- benzinga.com Pulse Biosciences Announced A New Publication In The Journal Thyroid, The First-in-human Clinical Feasibility Study Demonstrates The Effectiveness Of Ablation Of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation (nsPFA) Energy The study was designed to assess the ability of nsPFA energy to provide a safe and effective option for the treatment of symptomatic benign thyroid nodules with minimal side effects. The study was…
- benzinga.com Pulse Biosciences Q2 EPS $(0.28) Misses $(0.26) Estimate Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 40 percent decrease over losses of…
- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Oppenheimer Initiates Coverage On Pulse Biosciences with Outperform Rating, Announces Price Target of $22 Oppenheimer analyst Suraj Kalia initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Outperform rating and announces Price Target of $22.